Arypiprazol w dawce maksymalnej 30 mg i w połączeniu z olanzapiną

Abstract

Aripiprazole is an antipsychotic drug with unique pharmacological properties showing ago-antagonistic effects against the D2 receptor and is classified as a III generation antipsychotic. Clinical and preclinical studies indicate efficacy and safety of high doses of aripiprazole in selected patients, supporting the decision to use the drug at a maximum dose of 30 mg/day. This paper presents the mechanism of action of high doses of aripiprazole and discusses clinical situations when it is appropriate to use the drug at the maximum dose. The second part of the study presents arguments for beneficial effects of the combination of aripiprazole with olanzapine and other antipsychotic drugs of II generation.